Oceanpine and OrbiMed co-led the $130m Series B funding round for Yisheng Biopharma, a global biopharmaceutical company, headquartered in Beijing. Institutional investors also include: EightRoad, F-Prime Capital, 3W Capital, Hillhouse Capital, Adjuvant Capital, MSA Capital, AIHC, Epiphron Capital, Superstring Capital, Haitong International. This round of funding will strongly support the expansion of the company's R&D center, accelerate our commercialization strategies including the clinical development of multiple vaccine candidates and the construction of biologics production facilities in China and Singapore.